WO2007078922A3 - Micronized device for the delivery of biologically active molecules and methods of use thereof - Google Patents

Micronized device for the delivery of biologically active molecules and methods of use thereof Download PDF

Info

Publication number
WO2007078922A3
WO2007078922A3 PCT/US2006/048292 US2006048292W WO2007078922A3 WO 2007078922 A3 WO2007078922 A3 WO 2007078922A3 US 2006048292 W US2006048292 W US 2006048292W WO 2007078922 A3 WO2007078922 A3 WO 2007078922A3
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
methods
active molecules
delivery
micronized device
Prior art date
Application number
PCT/US2006/048292
Other languages
French (fr)
Other versions
WO2007078922A2 (en
Inventor
Konrad Kauper
Weng Tao
Paul Stabila
Original Assignee
Neurotech Usa Inc
Konrad Kauper
Weng Tao
Paul Stabila
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotech Usa Inc, Konrad Kauper, Weng Tao, Paul Stabila filed Critical Neurotech Usa Inc
Priority to JP2008548600A priority Critical patent/JP5247468B2/en
Priority to EP06849026A priority patent/EP1971288B1/en
Priority to US12/087,089 priority patent/US9265814B2/en
Priority to ES06849026T priority patent/ES2406716T3/en
Priority to CA2635534A priority patent/CA2635534C/en
Priority to AU2006332971A priority patent/AU2006332971B2/en
Publication of WO2007078922A2 publication Critical patent/WO2007078922A2/en
Publication of WO2007078922A3 publication Critical patent/WO2007078922A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from.
PCT/US2006/048292 2005-12-30 2006-12-18 Micronized device for the delivery of biologically active molecules and methods of use thereof WO2007078922A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2008548600A JP5247468B2 (en) 2005-12-30 2006-12-18 Micronized device for delivery of bioactive molecules and method of use thereof
EP06849026A EP1971288B1 (en) 2005-12-30 2006-12-18 Micronized device for the delivery of biologically active molecules and methods of use thereof
US12/087,089 US9265814B2 (en) 2005-12-30 2006-12-18 Micronized device for the delivery of biologically active molecules and methods of use thereof
ES06849026T ES2406716T3 (en) 2005-12-30 2006-12-18 Micronized device for the supply of biologically active molecules and method of use thereof
CA2635534A CA2635534C (en) 2005-12-30 2006-12-18 Micronized device for the delivery of biologically active molecules and methods of use thereof
AU2006332971A AU2006332971B2 (en) 2005-12-30 2006-12-18 Micronized device for the delivery of biologically active molecules and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75547805P 2005-12-30 2005-12-30
US60/755,478 2005-12-30

Publications (2)

Publication Number Publication Date
WO2007078922A2 WO2007078922A2 (en) 2007-07-12
WO2007078922A3 true WO2007078922A3 (en) 2008-08-07

Family

ID=38228768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048292 WO2007078922A2 (en) 2005-12-30 2006-12-18 Micronized device for the delivery of biologically active molecules and methods of use thereof

Country Status (7)

Country Link
US (2) US7820195B2 (en)
EP (1) EP1971288B1 (en)
JP (1) JP5247468B2 (en)
AU (1) AU2006332971B2 (en)
CA (1) CA2635534C (en)
ES (1) ES2406716T3 (en)
WO (1) WO2007078922A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8055336B1 (en) * 2001-10-19 2011-11-08 Alfred E. Mann Foundation For Scientific Research Method for removing surgically implanted devices
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
WO2009045370A2 (en) 2007-09-28 2009-04-09 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
RU2573912C2 (en) 2008-10-08 2016-01-27 Интрексон Корпорейшн Constructed cells, expressing multiple immunomodulators, and thereof application
AU2010206374B2 (en) 2009-01-23 2013-01-17 Gloriana Therapeutics Sarl Improved cell lines and their use in encapsulated cell biodelivery
US20100272780A1 (en) * 2009-04-23 2010-10-28 Vincent Ling CELL LINES THAT PRODUCE PROSTAGLANDIN F2 ALPHA (PGF2a) AND USES THEREOF
CA2776748A1 (en) * 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
EP3549617B1 (en) 2010-07-12 2023-09-13 University of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
EP2621403B1 (en) 2010-09-27 2015-03-18 NsGene A/S Implantable cell device with supportive and radial diffusive scaffolding
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
JP2014506119A (en) 2010-12-02 2014-03-13 ニューロテック ユーエスエー， インコーポレイテッド Cell lines secreting anti-angiogenic antibody scaffolds and soluble receptors and uses thereof
JPWO2012128363A1 (en) * 2011-03-24 2014-07-24 コスメディ製薬株式会社 PEDF microneedle array and manufacturing method thereof
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
US10478206B2 (en) 2011-04-29 2019-11-19 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
WO2013063383A2 (en) 2011-10-27 2013-05-02 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
WO2013177198A1 (en) 2012-05-21 2013-11-28 The Regents Of The University Of Colorado, A Body Corporate Ledgf peptides and formulations thereof for treatment of degenerative disorders
AU2013264859B2 (en) * 2012-05-25 2016-05-26 Kimberly-Clark Worldwide, Inc. Enhanced personal care absorbent articles
EP2854884A1 (en) * 2012-05-30 2015-04-08 Neurotech USA, Inc. Cryopreserved implantable cell culture devices and uses thereof
EP3398559A1 (en) 2013-03-07 2018-11-07 ViaCyte, Inc. 3-dimensional large capacity cell encapsulation device assembly
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
KR20160086819A (en) 2013-09-11 2016-07-20 뉴로테크 유에스에이, 인코포레이티드. Encapsulated cell therapy cartridge
TWI741980B (en) 2015-04-07 2021-10-11 大陸商四川藍光英諾生物科技股份有限公司 Biological brick and its use
HUE055344T2 (en) 2015-04-07 2021-11-29 Revotek Co Ltd Compositions for cell-based three dimensional printing
US10456356B2 (en) 2015-05-27 2019-10-29 Neurotech Usa, Inc. Use of encapsulated cell therapy for treatment of ophthalmic disorders
JP6818042B2 (en) 2016-11-11 2021-01-20 富士フイルム株式会社 Immune isolation membranes, transplant chambers, and transplant devices
WO2018088451A1 (en) 2016-11-11 2018-05-17 富士フイルム株式会社 Immunoisolation membrane, transplantation chamber, and transplantation device
US20180222145A1 (en) * 2017-02-07 2018-08-09 Kabushiki Kaisha Toshiba Fiber-oriented material and method for manufacturing the same
CN110831637B (en) 2017-06-29 2022-03-18 富士胶片株式会社 Transplantation chamber and transplantation device
WO2019004381A1 (en) 2017-06-29 2019-01-03 富士フイルム株式会社 Transplant chamber, method for producing transplant chamber, transplant device and method for fusing porous membrane
WO2019004378A1 (en) 2017-06-29 2019-01-03 富士フイルム株式会社 Transplant chamber and transplant device
EP3905885A4 (en) * 2019-01-04 2022-08-03 The Regents of the University of California Compositions and methods for promoting angiogenesis in the eye
JP6929424B2 (en) * 2019-01-17 2021-09-01 株式会社東芝 Manufacturing method of fiber alignment material
WO2021087476A1 (en) 2019-11-01 2021-05-06 Neurotech Usa, Inc. System, apparatuses, devices, and methods for packaging an analyte diffusive implantable device
CN111733174B (en) * 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） Isolated nucleic acid molecule and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156844A (en) * 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
WO1997034586A2 (en) * 1996-03-22 1997-09-25 Cytotherapeutics, Inc. Device and method for treating ophthalmic diseases
US6627422B1 (en) * 1998-04-13 2003-09-30 Neurotech S.A. Device containing cell-supporting yarn matrix encapsulated in a semi-permeable membrane
US20050089960A1 (en) * 2003-06-10 2005-04-28 Nsgene A/S Secretion of neublastin
US20050180957A1 (en) * 2004-01-16 2005-08-18 Scharp David W. Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
US20050287320A1 (en) * 2000-05-12 2005-12-29 Matregen Corp. Method of producing structures using centrifugal forces

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3615024A (en) 1968-08-26 1971-10-26 Amicon Corp High flow membrane
US4409331A (en) 1979-03-28 1983-10-11 Damon Corporation Preparation of substances with encapsulated cells
US4352833A (en) 1979-12-12 1982-10-05 Young, Prussin, Mgk, J.V. Adherent controlled release pesticides
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US5049493A (en) 1987-10-23 1991-09-17 California Institute Of Technology Enhancement of cell growth by expression of a cloned hemoglobin gene
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
DE3829752A1 (en) 1988-09-01 1990-03-22 Akzo Gmbh INTEGRAL ASYMMETRICAL POLYAETHERSULPHONE MEMBRANE, METHOD FOR THE PRODUCTION AND USE FOR ULTRAFILTRATION AND MICROFILTRATION
DE3829766A1 (en) 1988-09-01 1990-03-22 Akzo Gmbh METHOD FOR PRODUCING MEMBRANES
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
WO1991000119A1 (en) 1989-06-30 1991-01-10 Baxter International Inc. Implantable device
US5002661A (en) 1989-08-25 1991-03-26 W. R. Grace & Co.-Conn. Artificial pancreatic perfusion device
JPH0445179U (en) 1990-08-23 1992-04-16
US5167762A (en) 1991-01-02 1992-12-01 Micron Technology, Inc. Anisotropic etch method
US5762798A (en) 1991-04-12 1998-06-09 Minntech Corporation Hollow fiber membranes and method of manufacture
AU666118B2 (en) 1991-04-25 1996-02-01 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
WO1993000128A1 (en) 1991-06-28 1993-01-07 Brown University Research Foundation Renewable neural implant device and method
WO1993003901A1 (en) 1991-08-23 1993-03-04 W.R. Grace & Co. - Conn. Implantable immunoisolated therapeutic devices
CA2091302A1 (en) * 1992-03-11 1993-09-12 Ichiro Yoshida Semiconductor laser and process for fabricating the same
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
WO1995001203A2 (en) 1993-06-23 1995-01-12 Cytotherapeutics, Inc. Implantable membrane encapsulation apparatus
AU7568094A (en) 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1995024472A1 (en) * 1994-03-07 1995-09-14 The Regents Of The University Of California Microfabricated capsules for isolation of cell transplants
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
JP3634086B2 (en) 1996-08-13 2005-03-30 株式会社半導体エネルギー研究所 Method for manufacturing insulated gate type semiconductor device
US6421733B1 (en) 1997-03-25 2002-07-16 Intel Corporation System for dynamically transcoding data transmitted between computers
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US6267954B1 (en) 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156844A (en) * 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
WO1997034586A2 (en) * 1996-03-22 1997-09-25 Cytotherapeutics, Inc. Device and method for treating ophthalmic diseases
US6627422B1 (en) * 1998-04-13 2003-09-30 Neurotech S.A. Device containing cell-supporting yarn matrix encapsulated in a semi-permeable membrane
US20050287320A1 (en) * 2000-05-12 2005-12-29 Matregen Corp. Method of producing structures using centrifugal forces
US20050089960A1 (en) * 2003-06-10 2005-04-28 Nsgene A/S Secretion of neublastin
US20050180957A1 (en) * 2004-01-16 2005-08-18 Scharp David W. Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1971288A4 *

Also Published As

Publication number Publication date
US7820195B2 (en) 2010-10-26
EP1971288A2 (en) 2008-09-24
AU2006332971B2 (en) 2013-03-07
AU2006332971A1 (en) 2007-07-12
US9265814B2 (en) 2016-02-23
CA2635534C (en) 2014-07-29
US20110236457A1 (en) 2011-09-29
WO2007078922A2 (en) 2007-07-12
JP2009522269A (en) 2009-06-11
EP1971288A4 (en) 2011-11-09
JP5247468B2 (en) 2013-07-24
EP1971288B1 (en) 2013-02-13
US20070154524A1 (en) 2007-07-05
CA2635534A1 (en) 2007-07-12
ES2406716T3 (en) 2013-06-07

Similar Documents

Publication Publication Date Title
WO2007078922A3 (en) Micronized device for the delivery of biologically active molecules and methods of use thereof
EP1778335A4 (en) Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
WO2007025286A3 (en) Therapy procedure for drug delivery for trigeminal pain
WO2008054544A3 (en) Method for delivery across the blood brain barrier
EP1926521A4 (en) Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
IL172082A0 (en) Foamable pharmaceutical compositions and methods for treating a disorder
WO2007100745A3 (en) Apparatus and formulations for suprachoroidal drug delivery
IL178775A (en) Glucocorticoid-containing pharmaceutical composition for use in the treatment of disorders requiring acute glucocorticoid therapy
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2008036682A3 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2009086112A3 (en) Apparatus and methods for delivering therapeutic agents
EP2108390A3 (en) Device for local and/or regional delivery employing liquid formulations of therapeutic agents
ZA201003779B (en) Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
WO2007041300A3 (en) Iontophoresis method and apparatus for systemic delivery of active agents
WO2007089435A3 (en) Medical devices for therapeutic agent delivery
HK1145070A1 (en) Therapeutic use of a growth factor, metrnl
WO2009029958A3 (en) Implantable delivery device
WO2009142772A3 (en) Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
WO2006124681A3 (en) Oral drug delivery system and methods of use thereof
WO2007042040A3 (en) TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS
WO2011119227A3 (en) Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
WO2011133957A3 (en) Devices for delivering neuro-electro-adaptive therapy (neat)
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2635534

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008548600

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006332971

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006849026

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006332971

Country of ref document: AU

Date of ref document: 20061218

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12087089

Country of ref document: US